Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Eisai R&d Co., Ltd.

Sally T Ishizaka

Lynn D Hawkins

Atsushi Endo

Shawn Schiller

Hans J Hansen

Matthew Mackey

Roch Boivin

Eric Carlson

Sridhar Narayan

Takashi Satoh

Jeffrey Rose

Michael D Lewis

Chikako Ogawa

Daniel P Rossignol

Heather Davis

Scott Fields

Pamela McGuinness

Pamela McGuiness

J Eric Carlson

Mark Spyvee

Peter Bertinato

Wanjun Zheng

Hu Yang

Fabian Gusovsky

Robert Yu

Gregory Berger

Anneliese Nault

Robert T Yu

Scott Z Fields

Michael Lewis

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Tetrahydropyrazolopyrimidine compounds

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Selectively substituted quinoline compounds

The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

Compositions and methods for cancer immunotherapy

The present invention provides benzoxazole compounds and pharmaceutically acceptable salts thereof and pharmaceutical compositions including the same. The present invention further provides methods of use as described herein.

Benzoxazole compounds and methods of use

The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, therapeutic and prophylactic treatment of cancer, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.

Immunomodulatory compounds and methods of use thereof

The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.

The present invention is directed to novel compounds that function as immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases, to novel adjuvant formulations which include at least one of the adjuvant compounds of the invention, to novel immunostimulatory compositions which comprise an antigen and at least one of the adjuvant compounds of the invention, and to methods for the immunization of an animal by co-administration of a compound of the invention with an antigen against which the animal is to be immunized.

Growing community of inventors

Andover, MA, United States of America

Sally T Ishizaka